Top

Published in:

Open Access 01-12-2022 | Dyslipidemia | Research

Clinical and prognostic aspects of patients with the Neuromyelitis Optica Spectrum Disorder (NMOSD) from a cohort in Northeast Brazil

Authors: Thiago Gonçalves Fukuda, Ivã Taiuan Fialho Silva, Tayla Samanta Silva dos Santos, Marcos Baruch Portela Filho, Fernanda Ferreira de Abreu, Jamary Oliveira-Filho

Published in: BMC Neurology | Issue 1/2022

Abstract

Introduction

Neuromyelitis optica spectrum disorders (NMOSD) is a rare inflammatory and demyelinating disease of the central nervous system (CNS) more frequent in women and Afro-descendants. No previous epidemiological or prognostic study has been conducted in the region of the state of Bahia, Brazilian Northeast.

Objective

To evaluate clinical and prognostic aspects in patients with NMOSD from a cohort in northeastern Brazil.

Material and methods

A single-center retrospective study was conducted with consecutive patients diagnosed with NMOSD. Clinical and epidemiological characteristics were described. The degree of disability was expressed by the Expanded Disability Status Scale (EDSS). Worsening disability were analyzed through negative binomial regression adjusted for disease duration.

Results

Ninety-one patients were included, 72 (79.1%) female and 67 (73.6%) afro descendants. Mean age at onset was 36 (± 14) years and 73.3% were anti-aquaporin-4 antibody positive. Isolated transverse myelitis (32.9%) and isolated optic neuritis (22.4%) were the most frequent initial clinical syndromes. After multivariate analysis, optic neuritis (RR = 0.45; 95% CI = 0.23 – 0.88; p = 0.020) and dyslipidemia (RR = 0.40; 95% CI = 0.20 – 0.83; p = 0.014) were associated with slower disease progression. Area postrema involvement (RR = 6.70; 95% CI = 3.31 – 13.54; p < 0.001) and age at onset (RR = 1.03; 95% CI = 1.01 – 1.05; p = 0.003) were associated with faster disease progression.

Conclusions

In the first clinical and prognostic study in northeastern Brazil, we identified area postrema involvement, age at onset, optic neuritis at fist syndrome and dyslipidemia as the main prognostic factors associated with disease progression.

Available only for authorised users

Lennon V.A, Wingerchuk D.M, Kryzer T.J, Pittock S.J, Lucchinetti C.F, Fujihara K, Nakashima I, Weinshenker B.G. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004;364(9451):2106–12.CrossRef

Huda S, Whittam D, Bhojak M, Chamberlain J, Noonan C, Jacob A. Neuromyelitis optica spectrum disorders. Clin Med J R Coll Physicians London. 2019;19:169–76. https://doi.org/10.7861/CLINMEDICINE.19-2-169.CrossRef

Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, De Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015;85:177–89. https://doi.org/10.1212/WNL.0000000000001729.CrossRefPubMedPubMedCentral

Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology. 1999;53:1107–14. https://doi.org/10.1212/wnl.53.5.1107.CrossRefPubMed

Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007;6:805–15. https://doi.org/10.1016/S1474-4422(07)70216-8.CrossRefPubMed

Etemadifar M, Dashti M, Vosoughi R, Abtahi SH, Ramagopalan SV, Nasr Z. An epidemiological study of neuromyelitis optica in Isfahan. Mult Scler J. 2014;20:1920–2. https://doi.org/10.1177/1352458514537699.CrossRef

Mealy MA, Wingerchuk DM, Greenberg BM, Levy M. Epidemiology of neuromyelitis optica in the United States: A multicenter analysis. Arch Neurol. 2012;69:1176–80. https://doi.org/10.1001/archneurol.2012.314.CrossRefPubMed

Bichuetti DB, Oliveira EML, Souza NA, Rivero RLM, Gabbai AA. Neuromyelitis optica in Brazil: A study on clinical and prognostic factors. Mult Scler. 2009;15:613–9. https://doi.org/10.1177/1352458508101935.CrossRefPubMed

Fragoso Y.D, Sousa N.A.C, Alves-Leon S.V, Dias R.M, Pimentel M.L. V, Gomes S, Goncalves M.V.M, Stella C.V, Tauil C.B, Anacleto A, Spessotto C.V, Correa E.C, Eboni A.C.B, Damasceno A, Damasceno B, Farinhas J.G.D, de S. Mota R.S, Nogueira E.G.A, Pereira V.C.S.R, Scorcine C, Bacon T, Kister I. Clinical characteristics of 153 Brazilian patients with neuromyelitis optica spectrum disorder (NMOSD). Mult Scler Relat Disord. 2019;27:392–6. https://doi.org/10.1016/j.msard.2018.11.031.CrossRefPubMed

10.

Bukhari W, Clarke L, O’Gorman C, Khalilidehkordi E, Arnett S, Prain KM, Woodhall M, Silvestrini R, Bundell CS, Ramanathan S, Abernethy D, Bhuta S, Blum S, Boggild M, Boundy K, Brew BJ, Brownlee W, Butzkueven H, Carroll WM, Chen C, Coulthard A, Dale RC, Das C, Dear K, Fabis-Pedrini MJ, Fulcher D, Gillis D, Hawke S, Heard R, Henderson APD, Heshmat S, Hodgkinson S, Jimenez-Sanchez S, Kilpatrick TJ, King J, Kneebone C, Kornberg AJ, Lechner-Scott J, Lin MW, Lynch C, Macdonnell RAL, Mason DF, McCombe PA, Pereira J, Pollard JD, Reddel SW, Shaw C, Spies J, Stankovich J, Sutton I, Vucic S, Walsh M, Wong RC, Yiu EM, Barnett MH, Kermode AG, Marriott MP, Parratt J, Slee M, Taylor BV, Willoughby E, Wilson RJ, Brilot F, Vincent A, Waters P, Broadley SA. The clinical profile of NMOSD in Australia and New Zealand. J Neurol. 2020;267:1431–43. https://doi.org/10.1007/s00415-020-09716-4.CrossRefPubMed

11.

Domingos J, Isidoro L, Figueiredo R, Brum M, Capela C, Barros P, Santos E, Macário MDC, Pinto Marques J, Pedrosa R, Vale J, Sá MJ. Neuromyelitis optica in Portugal (NEMIPORT) - A multicentre study. Clin Neurol Neurosurg. 2015;134:79–84. https://doi.org/10.1016/j.clineuro.2015.04.001.CrossRefPubMed

12.

Alvarenga M, Schimidt S, Alvarenga RP. Epidemiology of neuromyelitis optica in Latin America. Mult Scler J. Exp Transl Clin. 2017;3:205521731773009. https://doi.org/10.1177/2055217317730098.CrossRef

13.

A. Maria, D. Zanette, M.D.S. Gonc, S. Bahia, L. Vasconcelos, A. Nogueira, M. Arruda, SICKLE CELL ANEMIA : DELAYED DIAGNOSIS IN BAHIA , BRAZIL - … the results of neonatal screening have shown that in Bahia , 1 in 650 children are born each year with SCD , a higher prevalence than any, Ethn Dis. 21 (2011) 243–247. http://www.ishib.org/ED/journal/21-2/ethn-21-02-243.pdf.

14.

Amaral JM, Talim N, Kleinpaul R, Lana-Peixoto MA. Optic neuritis at disease onset predicts poor visual outcome in neuromyelitis optica spectrum disorders. Mult Scler Relat Disord. 2020;41: 102045. https://doi.org/10.1016/j.msard.2020.102045.CrossRefPubMed

15.

Akman-Demir G, Tüzün E, Waters P, Içöz S, Kürtüncü M, Jarius S, Yapici Z, Mutlu M, Yeşilot N, Vincent A, Eraksoy M. Prognostic implications of aquaporin-4 antibody status in neuromyelitis optica patients. J Neurol. 2011;258:464–70. https://doi.org/10.1007/s00415-010-5780-4.CrossRefPubMed

16.

Kim SM, Waters P, Woodhall M, Kim YJ, Kim JA, Cheon SY, Lee S, Jo SR, Kim DG, Jung KC, Lee KW, Sung JJ, Park KS. Gender effect on neuromyelitis optica spectrum disorder with aquaporin4-immunoglobulin G. Mult Scler. 2017;23:1104–11. https://doi.org/10.1177/1352458516674366.CrossRefPubMed

17.

Kim SH, Mealy MA, Levy M, Schmidt F, Ruprecht K, Paul F, Ringelstein M, Aktas O, Hartung HP, Asgari N, Tsz-Ching JL, Siritho S, Prayoonwiwat N, Shin HJ, Hyun JW, Han M, Leite MI, Palace J, Kim HJ. Racial differences in neuromyelitis optica spectrum disorder. Neurology. 2018;91:E2089–99. https://doi.org/10.1212/WNL.0000000000006574.CrossRefPubMedPubMedCentral

18.

Kitley J, Leite MI, Nakashima I, Waters P, McNeillis B, Brown R, Takai Y, Takahashi T, Misu T, Elsone L, Woodhall M, George J, Boggild M, Vincent A, Jacob A, Fujihara K, Palace J. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain. 2012;135:1834–49. https://doi.org/10.1093/brain/aws109.CrossRefPubMed

19.

Jiao Y, Fryer JP, Lennon VA, Jenkins SM, Quek AML, Smith CY, McKeon A, Costanzi C, Iorio R, Weinshenker BG, Wingerchuk DM, Shuster EA, Lucchinetti CF, Pittock SJ. Updated estimate of AQP4-IgG serostatus and disability outcome in neuromyelitis optica. Neurology. 2013;81:1197–204. https://doi.org/10.1212/WNL.0b013e3182a6cb5c.CrossRefPubMedPubMedCentral

20.

Kurtzke J. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33:1444–52.CrossRef

21.

Weishenker BG, Ebers GC, Koopman WJ, Hader W, Sadovnick AD, Kremenchutzky M, Mandalfino P, Wingerchuk DM, Baskerville J, Rice GPA. The natural history of multiple sclerosis: A geographically based study. 8. Familial multiple sclerosis. Brain. 1989;123:641–9. https://doi.org/10.1093/brain/123.3.641.CrossRef

22.

Del Negro MC, Marinho PBC, Papais-Alvarenga RM. Neuromyelitis optica: phenotypic characteristics in a Brazilian case series. Arq Neuropsiquiatr. 2017;75:81–6. https://doi.org/10.1590/0004-282x20160193.CrossRefPubMed

23.

Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, Klawiter EC, Sato DK, De Seze J, Wuerfel J, Banwell BL, Villoslada P, Saiz A, Fujihara K, Kim SH. MRI characteristics of neuromyelitis optica spectrum disorder: An international update. Neurology. 2015;84:1165–73. https://doi.org/10.1212/WNL.0000000000001367.CrossRefPubMedPubMedCentral

24.

Asgari N, Lillevang ST, Skejoe HPB, Falah M, Stenager E, Kyvik KO. A population-based study of neuromyelitis optica in Caucasians. Neurology. 2011;76:1589–95. https://doi.org/10.1212/WNL.0b013e3182190f74.CrossRefPubMedPubMedCentral

25.

Sepúlveda M, Armangué T, Sola-Valls N, Arrambide G, Meca-Lallana JE, Oreja-Guevara C, Mendibe M, De Arcaya AA, Aladro Y, Casanova B, Olascoaga J, Jiménez-Huete A, Fernández-Fournier M, Ramió-Torrentà L, Cobo-Calvo A, Viñals M, De Andrés C, Meca-Lallana V, Cervelló A, Calles C, Rubio MB, Ramo-Tello C, Caminero A, Munteis E, Antigüedad AR, Blanco Y, Villoslada P, Montalban X, Graus F, Saiz A. Neuromyelitis optica spectrum disorders: Comparison according to the phenotype and serostatus. Neurol Neuroimmunol NeuroInflammation. 2016;3:1–9. https://doi.org/10.1212/NXI.0000000000000225.CrossRef

26.

F. ERC et al, Recomendações no tratamento da Esclerose Múltipla e Neuromielite Óptica, Departamento Científico de Neuroimunologia da ABN, São Paulo, 2016.

27.

Kang H, Chen T, Li H, Xu Q, Cao S, Wei S. Prognostic factors and disease course in aquaporin-4 antibody-positive Chinese patients with acute optic neuritis. J Neurol. 2017;264:2130–40. https://doi.org/10.1007/s00415-017-8606-9.CrossRefPubMed

28.

Ambika S, Balasubramanian M, Theresa L, Veeraputhiran A, Arjundas D. Aquaporin 4 antibody [NMO Ab] status in patients with severe optic neuritis in India. Int Ophthalmol. 2015;35:801–6. https://doi.org/10.1007/s10792-015-0048-8.CrossRefPubMed

29.

D.B. Bichuetti, A.B. Falcão, F. de C. Boulos, M.M. de Morais, C.B. de C. Lotti, M. de O. Fragomeni, M.F. Campos, N.A. de Souza, E.M.L. Oliveira, The profile of patients followed at the Neuroimmunology Clinic at UNIFESP: 20 years analysis, Arq. Neuropsiquiatr. 73 (2015) 304–308. https://doi.org/10.1590/0004-282X20150004.

30.

Shahmohammadi S, Doosti R, Shahmohammadi A, Mohammadianinejad SE, Sahraian MA, Azimi AR, Harirchian MH, Asgari N, NaserMoghadasi A. Autoimmune diseases associated with Neuromyelitis Optica Spectrum Disorders: A literature review. Mult Scler Relat Disord. 2019;27:350–63. https://doi.org/10.1016/j.msard.2018.11.008.CrossRefPubMed

31.

Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: Clinical predictors of a relapsing course and survival. Neurology. 2003;60:848–53. https://doi.org/10.1212/01.WNL.0000049912.02954.2C.CrossRefPubMed

32.

Bergamaschi R, Ghezzi A. Devic’s neuromyelitis optica: Clinical features and prognostic factors. Neurol Sci. 2004;25:364–7. https://doi.org/10.1007/s10072-004-0342-0.CrossRef

33.

Papathanasiou A, Tanasescu R, Tench CR, Rocha MF, Bose S, Constantinescu CS, Jacob S. Age at onset predicts outcome in aquaporin-4-IgG positive neuromyelitis optica spectrum disorder from a United Kingdom population. J Neurol Sci. 2021;431: 120039. https://doi.org/10.1016/j.jns.2021.120039.CrossRefPubMed

34.

Wang KC, Lee CL, Chen SY, Lin KH, Tsai CP. Prominent brainstem symptoms/signs in patients with neuromyelitis optica in a Taiwanese population. J Clin Neurosci. 2011;18:1197–200. https://doi.org/10.1016/j.jocn.2010.12.052.CrossRefPubMed

35.

Lu Z, Qiu W, Zou Y, Lv K, Long Y, You W, Zheng X, Hu X. Characteristic linear lesions and longitudinally extensive spinal cord lesions in Chinese patients with neuromyelitis optica. J Neurol Sci. 2010;293:92–6. https://doi.org/10.1016/j.jns.2010.02.026.CrossRefPubMed

36.

Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005;65:1479–82. https://doi.org/10.1212/01.wnl.0000183151.19351.82.CrossRefPubMed

37.

Wang Y, Zhang L, Zhang B, Dai Y, Kang Z, Lu C, Qiu W, Hu X, Lu Z. Comparative clinical characteristics of neuromyelitis optica spectrum disorders with and without medulla oblongata lesions. J Neurol. 2014;261:954–62. https://doi.org/10.1007/s00415-014-7298-7.CrossRefPubMed

38.

Wang Y, Wu A, Chen X, Zhang L, Lin Y, Sun S, Cai W, Zhang B, Kang Z, Qiu W, Hu X, Lu Z. Comparison of clinical characteristics between neuromyelitis optica spectrum disorders with and without spinal cord atrophy. BMC Neurol. 2014;14:1–7. https://doi.org/10.1186/s12883-014-0246-4.CrossRef

39.

Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: An amnesic process. Brain. 2003;126:770–82. https://doi.org/10.1093/brain/awg081.CrossRefPubMed

40.

Tintoré M, Rovira A, Rio J, Nos C, Grivé E, Téllez N, Pelayo R, Comabella M, Montalban X. Is optic neuritis more benign than other first attacks in multiple sclerosis? Ann Neurol. 2005;57:210–5. https://doi.org/10.1002/ana.20363.CrossRefPubMed

41.

Wu K, Wen LL, Duan R, Li Y, Yao Y, Jing L, Jia Y, Teng J, He Q. Triglyceride Level Is an Independent Risk Factor in First-Attacked Neuromyelitis Optica Spectrum Disorders Patients. Front Neurol. 2019;10:1–9. https://doi.org/10.3389/fneur.2019.01230.CrossRef

42.

Antonopoulos AS, Margaritis M, Lee R, Channon K, Antoniades C. Statins as Anti-Inflammatory Agents in Atherogenesis: Molecular Mechanisms and Lessons from the Recent Clinical Trials. Curr Pharm Des. 2012;18:1519–30. https://doi.org/10.2174/138161212799504803.CrossRefPubMedPubMedCentral

43.

Khovidhunkit W, Kim MS, Memon RA, Shigenaga JK, Moser AH, Feingold KR, Grunfeld C. Effects of infection and inflammation on lipid and lipoprotein metabolism: Mechanisms and consequences to the host. J Lipid Res. 2004;45:1169–96. https://doi.org/10.1194/jlr.R300019-JLR200.CrossRefPubMed

Title: Clinical and prognostic aspects of patients with the Neuromyelitis Optica Spectrum Disorder (NMOSD) from a cohort in Northeast Brazil
Authors: Thiago Gonçalves Fukuda
Ivã Taiuan Fialho Silva
Tayla Samanta Silva dos Santos
Marcos Baruch Portela Filho
Fernanda Ferreira de Abreu
Jamary Oliveira-Filho
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Dyslipidemia
Optic Neuritis
Neuromyelitis Optica Spectrum Disease
Published in: BMC Neurology / Issue 1/2022
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-022-02621-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinical and prognostic aspects of patients with the Neuromyelitis Optica Spectrum Disorder (NMOSD) from a cohort in Northeast Brazil

Abstract

Introduction

Objective

Material and methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Introduction

Objective

Material and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2022

Effect of insomnia in the major depressive disorder

Inactivated COVID-19 vaccine induced acute stroke-like focal neurologic symptoms: a case series

Preliminary study on brain resting-state networks and cognitive impairments of patients with obstructive sleep apnea–hypopnea syndrome

What is the added value of CT-angiography in patients with transient ischemic attack?

Cerebral blood flow abnormalities with central sparing on arterial spin labeling in mild encephalopathy associated with excitotoxicity: a case report

“Incidence, characteristics and prognosis of cervical artery dissection-induced ischemic stroke in central Iran”